Literature DB >> 32650535

Role of Helicobacters in Neuropsychiatric Disease: A Systematic Review in Idiopathic Parkinsonism.

Rosalind M Tucker1,2, Aisha D Augustin1,2, Bu' Hussain Hayee3, Ingvar Bjarnason3, David Taylor1,2, Clive Weller1, André Charlett1,4, Sylvia M Dobbs1,2,3, R John Dobbs1,2,3.   

Abstract

Interest in an aetiopathogenic role for Helicobacter in neuropsychiatric diseases started with idiopathic parkinsonism (IP), where the cardinal signs can be assessed objectively. This systematic review, using an EMBASE database search, addresses Oxford Centre for Evidence-Based Medicine based questions on the inter-relationship of Helicobacter and IP, the benefits of eradicating Helicobacter in IP and the outcome of not treating. The search strategy was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines: 21 of 204 articles met the inclusion criteria. The results show that the assumption that any benefit of Helicobacter eradication results from improved levodopa bioavailability is unjustified. The inter-relationship between Helicobacter and IP is well-established. H. pylori virulence markers (associated with autoimmunity and immune tolerance) influence the risk, severity and progression of IP. The birth cohort effect for virulence marker antibodies, seen in controls, is obliterated in IP, suggesting causality. Successful H. pylori eradication in IP is disease-modifying (even in anti-parkinsonian treatment-naïve patients) but not preventive. Hypokinesia regresses with eradication and overall motor severity lessens. Eradication may influence gastrointestinal microbiota adversely, unlocking the next stage in the natural history, the development of rigidity. Failed eradication worsens hypokinesia, as does the presence/persistence of H. pylori at molecular level only. Adequate prognostic assessment of the consequences of not treating Helicobacter, for IP, is prevented by a short follow-up. We conclude that Helicobacter is a pathophysiological driver of IP.

Entities:  

Keywords:  Helicobacter pylori; Parkinson’s disease; aetiopathogenesis; brady/hypokinesia; eradication; non-Helicobacter pylori Helicobacters; rigidity; virulence markers

Year:  2020        PMID: 32650535     DOI: 10.3390/jcm9072159

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  1 in total

1.  Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease.

Authors:  Jonas Ghyselinck; Lynn Verstrepen; Frédéric Moens; Pieter Van Den Abbeele; Arnout Bruggeman; Jawal Said; Barry Smith; Lynne Ann Barker; Caroline Jordan; Valentina Leta; K Ray Chaudhuri; Abdul W Basit; Simon Gaisford
Journal:  Int J Pharm X       Date:  2021-07-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.